Drug intelligence / Profile preview

Balvibe

Development stage: Unknown
Lead developer: Bal Pharma
Modality: Small Molecules
Administration: Oral

Overview

Balvibe is a nutritional supplement developed and marketed by Bal Pharma Limited, primarily in the Indian market. It is formulated as a softgel capsule containing a combination of 500 mg of flaxseed oil, 5 mg of folic acid, and 0.001 mg (1 mcg) of cyanocobalamin (Vitamin B12). The flaxseed oil component serves as a rich source of alpha-linolenic acid (ALA), an omega-3 fatty acid that supports cardiovascular health and joint function. Folic acid and Vitamin B12 are essential vitamins that play critical roles in DNA synthesis, red blood cell production (erythropoiesis), and the maintenance of neurological health. Balvibe is positioned within Bal Pharma's portfolio to support energy metabolism, cognitive function, and overall wellness.

Brand names: Balvibe

Beyond the preview

Go deeper on Balvibe.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Balvibe.

Explore the full profile